✦ LIBER ✦

Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody

✍ Scribed by Marc-Francois Baudrihaye; Lucienne Chatenoud; Henry Kreis; Gideon Goldstein; Jean-Francois Bach

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 639 KB
Volume: 14
Category: Article
ISSN: 0014-2980
DOI: 10.1002/eji.1830140803

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Frequent anti-V-region immune response t

Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody

✍ M. B. Khazaeli; Mansoor N. Saleh; Tiepu Liu; Paul M. Kaladas; Steve C. Gilman; A 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 693 KB

Human T cell activation: differential re

Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies

✍ Jay M. Bjorndahl; Sun-Sang J. Sung; John A. Hansen; Shu Man Fu 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 819 KB

Isotype-specific immune response to a si

Isotype-specific immune response to a single hepatitis C virus core epitope defined by a human monoclonal antibody: diagnostic value and correlation to PCR

✍ K. Siemoneit; M. da Silva Cardoso; A. Wölpl; S. Epple; H. Wintersinger; K. Koern 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 566 KB

Monoclonal anti-idiotypic antibody mimic

Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small-cell lung carcinoma

✍ Andreas Barth; Robert Waibel; Rolf A. Stahel 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 550 KB

We have previously described the tumor-asrocisited sialoglycoprotein antigen sGP,,,, defined by the murine LAME MAb. The antigen is characterized by strong memlbrane expression in a proportion of small-cell carcinomas of the lung, but little or no expression on normal tissues of epithelial or neural

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views